Suc-Ala-Ala-Pro-Phe-pNA | 107409-54-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Suc-Ala-Ala-Pro-Phe-pNA
• 英文别名: succinyl-Ala-Ala-Pro-Phe-p-nitroanilide；(2S)-1-[(2S)-2-[[(2S)-2-(2,5-dioxopyrrolidin-1-yl)propanoyl]amino]propanoyl]-N-[(2S)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
• CAS: 107409-54-1
• 化学式: C₃₀H₃₄N₆O₈
• 分子量: 606.635
• InChiKey: OPPQPKUNOZKSCW-WJNSRDFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  44
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  191
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Suc-Ala-Ala-Pro-Phe-pNA 在 α-chymotrypsin (Type II) from bovine pancreas 、 C₈₄H₁₂₀N₈O₂₄ 作用下， 生成 4-硝基苯胺
  参考文献：
  名称：

  N-Linked Peptidoresorc[4]arene-Based Receptors as Noncompetitive Inhibitors for α-Chymotrypsin

  摘要：

  This paper deals with the design, synthesis, and evaluation of a new series of receptors for protein surface recognition. The design of these agents is based around the attachment of four constrained dipeptide chains onto a central resorc[4]arene scaffold. By varying the sequence, nature, and stereochemistry of the chains we prepared anionically functionalized N-linked peptidoresorc[4]arenes 12, 13, and 17 by Pd/C-catalyzed hydrogenation of the corresponding benzyl esters 10, 11, and 16, From this family of receptors we have identified noncompetitive inhibitors of alpha-chymotrypsin (ChT), which function by binding to the surface of the enzyme in the neighborhood of the active site cleft (K-i values ranging from 12.4 +/- 5.1 mu M for free carboxylic acid (+)-12b to 0.76 +/- 0.14 mu M for benzyl ester (-)-16a). For anionically functionalized receptors 12, 13, and 17 the ChT inhibition is based essentially on electrostatic interaction, and the bound enzyme can be released from the resorcarene surface by increasing the ionic strength, with its activity almost completely restored. For receptors with terminal benzyl ester groups (10 and 16) a hydrophobic network can be suggested.

  DOI：

  10.1021/jo102592f

文献信息

• Substituted phenyl acetamides and their use as protease inhibitors
  申请人：——

  公开号：US20040254166A1

  公开（公告）日：2004-12-16

  Phenyl acetamide compounds are described, including compounds of Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 3 -R 6 , R 11 , B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  苯乙酰胺化合物的描述，包括式I的化合物： 或其溶剂化合物、水合物或药用可接受盐；其中R 3 -R 6 ，R 11 ，B，Y和W在说明书中列出。本发明的化合物是蛋白酶的强效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶和Xa因子。描述了用于抑制血小板丢失、抑制血小板聚集物形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于制造用于血液采集、血液循环和血液储存的设备中的材料中，如导管、血液透析机、血液采集器和管、血管和支架。此外，这些化合物可以被检测标记并用于体内血栓的成像。
• Trisubstituted carbocyclic cyclophilin binding compounds and their use
  申请人：——

  公开号：US20020165275A1

  公开（公告）日：2002-11-07

  The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.

  本发明涉及一种新型的非肽类小有机化合物，其具有与环肽亚精蛋白（CyP）型免疫蛋白亲和力，并且涉及包含所述化合物中的一个或多个的药物组合物。该发明还涉及这些化合物和组合物用于结合CyP型蛋白，抑制其肽基脯氨酸异构酶活性，并在各种医学疾病的研究、开发和治疗应用中的用途。
• Modified peptide derivatives and methods of use thereof
  申请人：——

  公开号：US20040077829A1

  公开（公告）日：2004-04-22

  The present invention relates to a compound of formula I 1 wherein (i) when a and c are double bonds, R 2 is absent, b is a single bond, R 1 is 2 or (ii) when a and c are single bonds, b is a double bond, and R 1 is H, R 2 is 3 wherein X is straight or branched chain C 1-6 alkyl, —(CH 2 ) n Ar, C 1-6 cycloalkyl, or —(CH 2 ) n R″, where R″ is a cyclic hydrocarbyl group; Y is a natural or unnatural amino acid side chain; W is OH or NHR 3 , wherein R 3 is —CH(Y′)CO 2 X′, where X′ and Y′ are defined as for X and Y respectively, and may be the same or different to X and Y respectively; and Z 1 and Z 2 are each independently H, straight or branched chain C 1-6 alkyl, straight or branched chain C 1-6 alkenyl, —(CH 2 ) n Ar, —(CH 2 ) n —CO 2 R′, —(CH 2 ) p —CH═CH—(CH 2 ) q Ar where p and q are each independently 0 to 5, R′ is C 1-6 alkyl; and each n may be the same or different and is from 1 to 5.

  本发明涉及一种具有以下式I的化合物： 其中 (i) 当a和c为双键时，R2不存在，b为单键，R1为2或 (ii) 当a和c为单键时，b为双键，R1为H，R2为3 其中X为直链或支链C1-6烷基，—(CH2)nAr，C1-6环烷基，或—( )nR″，其中R″为环烷基羟基烷基； Y为天然或非天然氨基酸侧链； W为OH或NHR3，其中R3为—CH(Y′)CO2X′，其中X′和Y′分别定义如X和Y，且可能与X和Y分别相同或不同；以及 Z1和Z2各自独立地为H，直链或支链C1-6烷基，直链或支链C1-6烯基，—( )nAr，—( )n—CO2R′，—( )p—CH=CH—( )qAr，其中p和q各自独立地为0至5，R′为C1-6烷基； 每个n可以相同也可以不同，范围为1至5。
• [EN] NOVEL ORAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DIABETES<br/>[FR] COMPOSITION PHARMACEUTIQUE ORALE D'UN NOUVEAU TYPE DESTINÉE AU TRAITEMENT DU DIABÈTE
  申请人：NOVO NORDISK AS

  公开号：WO2014191545A1

  公开（公告）日：2014-12-04

  The invention provides improved solid oral pharmaceutical compositions comprising an insulin peptide or GLP-1 peptide and methods of producing such.

  这项发明提供了包含胰岛素肽或GLP-1肽的改进固体口服药物组合物，以及生产这种组合物的方法。
• Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals

  公开号：US20020061872A1

  公开（公告）日：2002-05-23

  Phenyl acetamide compounds are described, including compounds of Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 3 -R 6 , R 11 , B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  苯乙酰胺化合物的描述，包括式I的化合物： 或其溶剂化物、水合物或药学上可接受的盐；其中R 3 -R 6 ，R 11 ，B，Y和W在规范中列出。本发明的化合物是蛋白酶的强效抑制剂，特别是类似胰蛋白酶的丝氨酸蛋白酶，如凝血酶和Xa因子。描述了用于抑制血小板丢失、抑制血小板聚集物形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于制造用于血液采集、血液循环和血液储存的设备中的材料，如导管、血液透析机、血液采集注射器和管、血管和支架。此外，这些化合物可以被检测标记并用于体内血栓的成像。